Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced the initiation of a program to develop its intranasal foralumab, a fully human CD3 antibody, for treating or preventing Type 1 Diabetes. Following the $2.9 billion acquisition of Provention Bio by Sanofi, CD3 antibodies have become an attractive target in diabetes treatments. Foralumab’s unique delivery method aims to provide a non-injection alternative that might enhance patient compliance. The company plans to commence Phase 2 trials in non-active Secondary Progressive Multiple Sclerosis (SPMS) in the third quarter of 2023. The ongoing discussions with diabetes experts will refine the study designs for foralumab, which has previously shown promise in various chronic diseases and patient safety.
Tiziana Life Sciences (NASDAQ: TLSA) is developing foralumab, the first fully human anti-CD3 monoclonal antibody aimed at treating late-stage Multiple Sclerosis (MS). This innovative treatment functions through a nasal spray and modulates the immune system, specifically targeting regulatory T-cells to reduce brain inflammation. Recent research published in Proceedings of the National Academy of Sciences highlighted foralumab's efficacy in lowering inflammation in both COVID-19 and MS patients. Initial results from an open-label program showed promising outcomes for a patient previously on ocrelizumab, with his Expanded Disability Status Scale (EDSS) score improving significantly. Encouraged by these findings, Tiziana plans to initiate a Phase 2 trial in Q3 2023, focusing on long-term efficacy and safety of foralumab in MS treatment.
Tiziana Life Sciences (Nasdaq: TLSA) announced plans to investigate intranasal foralumab as a potential treatment for Long COVID, a condition affecting over 9 million Americans and costing the U.S. healthcare system approximately $2.6 trillion. The company emphasizes foralumab's role in deactivating activated microglia, critical in Long COVID's pathogenesis. Tiziana aims to enter a Phase 2a clinical trial pending FDA approval, using PET scans to assess the medication's effectiveness in reducing activated microglia after three months of use. The company believes that foralumab could represent a novel treatment for this debilitating condition, potentially benefiting a large patient population and addressing a significant unmet medical need.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced poster presentations on its lead asset, intranasal foralumab, at the "Preserving the Brain" scientific conference in Shanghai, running from March 31 to May 21, 2023. The event aims to foster discussions on neurodegenerative diseases among international experts. Gabriele Cerrone, Executive Chairman of Tiziana, expressed enthusiasm for foralumab's presentation, highlighting it as the only fully human anti-CD3 monoclonal antibody. Foralumab modulates T cell function which may aid in treating inflammatory conditions. Phase 2 trials for intranasal foralumab in patients with non-active SPMS are anticipated to begin in Q3 2023.
Tiziana Life Sciences (TLSA) announced promising findings related to the treatment of hemorrhagic stroke using intranasal anti-CD3 monoclonal antibodies. Dr. Saef Izzy's data indicates significant behavioral improvement in an animal model within one month post-treatment, supported by modulation of neuroinflammation through FoxP3+ Tregs. The research will be presented at the Annual American Academy of Neurology conference on April 23, 2023. The company aims to advance the clinical development of foralumab, the only fully human anti-CD3 monoclonal antibody, potentially transforming therapy for hemorrhagic stroke and improving neurological recovery outcomes.
Tiziana Life Sciences (TLSA) has announced plans to advance foralumab, a fully human anti-CD3 monoclonal antibody, into human trials targeting hemorrhagic stroke. Recent pre-clinical data indicates significant behavioral improvement in motor and cognitive functions one month after treatment in a model of intracerebral hemorrhage. The mechanism involves modulation of neuroinflammation through the induction of FoxP3+ Tregs, which may lead to enhanced recovery in stroke patients. Tiziana is actively pursuing clinical development, with Phase 2 trials of intranasal foralumab anticipated to initiate in Q3 2023.
Tiziana Life Sciences (NASDAQ: TLSA) announced promising results from a study on intranasal anti-CD3 monoclonal antibody for Alzheimer’s disease, to be presented at the AD/PD 2023 Conference on April 1, 2023. The study indicates reduced microglia activation and improved behavior in rodent models, suggesting that targeting neuroinflammation may enhance existing Alzheimer’s treatments. Dr. Howard Weiner highlighted that the research could complement FDA-approved therapies like aducanumab and lecanemab. Tiziana plans to initiate Phase 2 trials with foralumab in the third quarter of 2023, focusing on its immunomodulatory effects.
Summary not available.
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Chairman and Acting CEO, Gabriele Cerrone, acquired 8,000 common shares at $0.89 each, raising his total holdings to 38,701,237 shares. The company specializes in breakthrough immunotherapies with innovative drug delivery methods. Its lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody, showing potential in treating inflammatory diseases and demonstrating a favorable safety profile in initial studies. Phase 2 trials for foralumab are scheduled to begin in Q3 2023 for patients with non-active secondary progressive multiple sclerosis (SPMS).
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that Chairman and Acting CEO Gabriele Cerrone acquired 25,000 shares at $0.58 each, increasing his total ownership to 38,640,737 shares. The company focuses on developing immunomodulation therapies, particularly its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Phase 2 trials for foralumab are anticipated to commence in Q3 2023, targeting patients with non-active Secondary Progressive Multiple Sclerosis (SPMS). This innovative treatment route aims to enhance efficacy and tolerability compared to traditional IV delivery methods.